A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

Active:	Yes
Cancer Type:	Colon/Rectal Cancer Liver Cancer / Hepatoblastoma Melanoma	NCT ID:	NCT05091346
Trial Phases:	Phase I Phase II	Protocol IDs:	E7386-G000-201 (primary) NCI-2022-02226 2021-001568-10 KEYNOTE-C83
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Eisai Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT05091346

Summary

The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386
in combination with pembrolizumab in participants with previously treated selected solid
tumors, and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with
pembrolizumab.

The Phase 2 part of this study is conducted to assess the objective response rate (ORR) of
E7386 in combination with pembrolizumab (melanoma, colorectal cancer [CRC], hepatocellular
carcinoma [HCC]) or of E7386 in combination with pembrolizumab plus lenvatinib (HCC)
according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.